Related Experiment Video
Updated: Dec 18, 2025
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Are lupus animal models useful for understanding and developing new therapies for human SLE?
Erica Moore1, Chaim Putterman2
1Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract:
Systemic lupus erythematosus is a systemic autoimmune disease driven by a complex combination of genetic, environmental, and other immunoregulatory factors. The development of targeted therapies is complicated by heterogeneous clinical manifestations, varying organ involvement, and toxicity. Despite advances in understanding the mechanisms contributing to SLE, only one biologic drug, belimumab, is FDA-approved. The identification and development of potential therapies have largely been driven by studies in lupus animal models. Therefore, direct comparison of both the therapeutic and immunological findings in human and murine SLE studies is critical and can reveal important insights into indeed how useful and relevant are murine studies in SLE drug development. Studies involving belimumab, mycophenolate mofetil, abatacept, rituximab, and anti-interferon strategies generally demonstrated analogous findings in the attenuation of SLE manifestations and modulation of select immune cell populations in human and murine SLE. While further basic and translational studies are needed to identify SLE patient subsets likely to respond to particular therapeutic modalities and in dissecting complex mechanisms, we believe that despite some inherent weaknesses SLE mouse models will continue to be integral in developing targeted SLE therapies.
Insights
Comparing human and mouse lupus studies reveals that animal models are crucial for developing new systemic lupus erythematosus (SLE) therapies, despite some limitations. These models help evaluate drug efficacy and immune responses, guiding future treatment strategies for SLE.
Area of Science:
- Immunology
- Rheumatology
- Translational Medicine
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical presentations and limited targeted therapies.
- Belimumab is the only FDA-approved biologic drug for SLE, highlighting the need for novel therapeutic strategies.
- Drug development for SLE heavily relies on animal models, necessitating an evaluation of their translational relevance.
Purpose of the Study:
- To critically compare therapeutic and immunological findings from human and murine SLE studies.
- To assess the utility and relevance of lupus mouse models in the development of targeted SLE therapies.
Main Methods:
- Comparative analysis of therapeutic outcomes and immunological data from human SLE patients and lupus animal models.
- Review of studies involving key therapeutic agents such as belimumab, mycophenolate mofetil, abatacept, rituximab, and anti-interferon strategies.
Main Results:
- Studies using belimumab, mycophenolate mofetil, abatacept, rituximab, and anti-interferon treatments showed similar effects in attenuating SLE manifestations and modulating immune cells in both human and murine models.
- Analogous findings in therapeutic efficacy and immune modulation suggest a degree of translational validity for SLE mouse models.
Conclusions:
- Despite inherent limitations, SLE mouse models provide valuable insights and will remain integral to developing targeted therapies for SLE.
- Further basic and translational research is essential to identify patient subsets responsive to specific treatments and to elucidate complex disease mechanisms.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:21EPS and iPS Cells in Disease Research